Prelude Therapeutics (PRLD) Capital Expenditures (2019 - 2025)

Prelude Therapeutics has disclosed Capital Expenditures across 7 years of filings, most recently posting $20000.0 for Q2 2025.

• Capital Expenditures for Q2 2025 came in at $20000.0, down 94.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $20000.0 (up 108.62% YoY), and the FY2025 annual result was $67000.0, up 570.0% from the prior year.
• Capital Expenditures came in at $20000.0 for Q2 2025 at Prelude Therapeutics, down from $47000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.4 million in Q2 2022 to a low of -$2.5 million in Q4 2022.
• The 5-year median for Capital Expenditures is $356500.0 (2022), against an average of $333500.0.
• Across the five-year window, Capital Expenditures soared 2159.38% in 2021 and tumbled 953.87% in 2022, its largest moves.
• Prelude Therapeutics' Capital Expenditures stood at $297000.0 in 2021, then sank by 953.87% to -$2.5 million in 2022, then soared by 144.52% to $1.1 million in 2023, then plunged by 162.09% to -$701000.0 in 2024, then jumped by 102.85% to $20000.0 in 2025.
• The last three Capital Expenditures figures came in at $20000.0 (Q2 2025), $47000.0 (Q1 2025), and -$701000.0 (Q4 2024), per Business Quant data.